We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content. Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.
(ACS) Mar 23, 2017 - The American Cancer Society and a coalition of leading professional, government and non-governmental organizations are coming together to form the National Lung Cancer Roundtable to accelerate the nation's efforts to reduce mortality from lung cancer.
(STAT Plus) Mar 23, 2017 - Among the drug industry’s least-escapable buzzphrases is “value-based contracting,” a system under which payers shell out for pricey drugs only when they work, creating a theoretical win-win that increases access and cuts costs all the while.
(AMP) Mar 22, 2017 - The Association for Molecular Pathology (AMP), the premier global, non-profit molecular diagnostics professional society, today published consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients.
(FDA.gov) Mar 23, 2017 - The U.S. Food and Drug Administration today granted accelerated approval to Bavencio (avelumab) for the treatment of adults and pediatric patients 12 years and older with metastatic Merkel cell carcinoma (MCC), including those who have not received prior chemotherapy.
(STAT Plus) Mar 22, 2017 - It’s been a rough nine months for Bristol-Myers Squibb, between disappointing trial results, mounting competition, and some unwelcome attention from activist investors.
(ASCO) Mar 22, 2017 - The U.S. cancer care delivery system is undergoing profound changes to better meet the needs of people with cancer, but persistent hurdles threaten to slow progress, according to the American Society of Clinical Oncology’s (ASCO) fourth annual State of Cancer Care in America report released today.
(PharmaTimes [UK]) Mar 23, 2017 - An experimental therapy in development by Shire for patients with the rare blood disorder hereditary thrombotic thrombocytopenic purpura (hTTP) has been granted a fast track designation by the US Food and Drug Administration.
(STAT) Mar 22, 2017 - The new administration’s recently proposed “budget blueprint” aims to slash the nation’s investment in biomedical research by nearly 20 percent. This makes no sense for our patients, our citizens, or our scientists.
(BioPharma Reporter) Mar 22, 2017 - Amgen has signalled its intention to take a share of the $6.9bn Herceptin market by filing its trastuzumab candidate in the EU.
(University of Helsinki [Finland]) Mar 23, 2017 - The international CLUE Working Group studied the risk of thrombosis and severe haemorrhage after urological cancer operations and other forms of urological surgery.